Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
accident, Adipose, advisory, Affordable, aliability, approach, balloon, Brazil, Buerger, calf, cc, cholesterol, choose, concurrent, cooperation, costly, coverage, description, dilation, Endovascular, exceed, familiarity, FDIC, Framingham, GASP, Hadassah, halt, Hemopoietic, hiring, IC, IM, issuable, launch, leverage, margin, mononuclear, MTM, multilayered, multinational, narrowing, NYU, obesity, orphan, overallotment, PAH, pivotal, PLTR, pre, preserve, problem, profile, Progenitor, Pulmonary, QTDP, relationship, resale, Singapore, sit, strategy, suited, surgery, threatening, ticker, today, underwritten, upfront, USD, vast, widen, worsening
Removed:
accompany, acted, adding, advice, aggravated, aggressively, anniversary, authoritative, Avinoam, BCRT, bid, borrow, classify, college, commenced, creation, customary, debt, decrease, dedicated, default, dilution, directed, Disposal, doubling, Dov, Dr, earliest, embedded, endpoint, escrow, evaluated, extremity, failed, falling, FAS, favourable, feet, Finally, formation, FSP, fundraising, Gamida, hypercholesterolemia, IBD, immunological, immunomodulatory, impair, incidence, indexed, initiation, investigated, jeopardizing, Kadouri, lack, Le, liquidated, LLB, LLM, marketable, mechanism, microstructure, naturally, noted, obstruction, occlusive, occurred, operate, PAOD, patented, perfusion, physiological, practiced, privileged, Professor, profitably, PVD, receipt, recipient, recurring, reflection, repay, reproduce, resultant, Rishon, satisfy, secretion, settled, settlement, Shai, spend, spent, structure, submitted, subset, suspended, Task, Translation, unissued, unlimited, upgrading, vascular, vessel, viability, widely, worked, Zion, Zipori
Filing tables
Filing exhibits
PLUR similar filings
Filing view
External links
Exhibit 10.8
Summary of Directors Ongoing Compensation
As of June 30, 2011 our non-executive officer directors receive cash compensation as follows:
· | Annual compensation of $12,500; |
· | Meeting participation fee of $935 per in-person meeting; and |
· | For meeting participation by telephone, $435 per meeting. |
If the compensation is paid in New Israeli Shekels (“NIS”), the exchange rate of the directors’ fees used to calculate the fees will be not less then $4.25 per NIS.
The directors are also entitled to two and a half percent (2.5%) from amounts received by us from non diluting funding and strategic deals.